Latest Haemophilia Stories

47-year-old Texan is cycling 3,456 miles from California to Massachusetts to remember lost family and friends and help people suffering with hemophilia in developing countries. Georgetown, MA (PRWEB) May 13, 2013 Cyclist Barry Haarde commenced his second cross-country bike tour, “Wheels for the World 2013: Fast and Furious,” in Costa Mesa, California on April 20 to raise funds for Save One Life. Save One Life supports over 1,000 impoverished children and adults with hemophilia in 11...

Kcentra(TM) Is the First FDA-Approved 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in the U.S. KING OF PRUSSIA, Pa., April 30, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra(TM) (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g.,...

MONTREAL, April 16, 2013 /PRNewswire/ -- The global bleeding disorders community will come together on April 17 to mark World Hemophilia Day. This event takes on a special significance as it coincides with the 50(th) anniversary of the World Federation of Hemophilia (WFH). To commemorate its 50(th) anniversary, the WFH has launched a hemophilia awareness video entitled The Journey Begins. It explores the origins of the WFH and the inspired role that Frank Schnabel played in bringing...

CSL Behring initiates first "installment" of renewed 3-year commitment to WFH to donate coagulation factor to the WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 3, 2013 /PRNewswire/ -- As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day this month. The medicine will be used in treating patients in...

WebTracker-Hemophilia Software Used as the National Information Infrastructure Given New Brand Name HemaGlobal for Overseas Markets SAN FRANCISCO, April 2, 2013 /PRNewswire/ -- GZS, Inc., a leader in developing disease-specific and condition-specific Electronic Medical Records/Electronic Health Records (EMR/EHR) and patient registry software solutions, has announced the worldwide release of the WebTracker-Hemophilia((TM)) EHR patient registry solution used under the new brand name...

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with...

BEDFORD, Mass., Feb. 5, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar von Willebrand Factor (VWF) assay panel as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The CE IVD Mark allows IL to commence distribution of the product in the European Union and other international territories. The fully automated HemosIL AcuStar VWF assay panel, designed exclusively for use on...

KING OF PRUSSIA, Pa., Jan. 30, 2013 /PRNewswire/ -- CSL Behring announced today that it has awarded $78,750 in Local Empowerment for Advocacy Development (LEAD) grants to patient advocacy organizations in New York and Ohio, and to the American Plasma Users Coalition (APLUS). LEAD grants are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or creating a new one. (Logo:...

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with...